Clinical review report: Semaglutide (Ozempic) (Novo Nordisk Canada Inc.)
The objective of this review was to perform a systematic review of the beneficial and harmful effects of semaglutide (SEM) at the recommended dose for the treatment of adult patients with Type 2 diabetes mellitus
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
June 2019, 2019
|
Edition: | Final (with redactions) |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this review was to perform a systematic review of the beneficial and harmful effects of semaglutide (SEM) at the recommended dose for the treatment of adult patients with Type 2 diabetes mellitus |
---|---|
Physical Description: | 1 PDF file (149 pages) illustrations |